The Protein Design Revolution Begins Here

Neoleukin’s lead program, NL-201, is believed to be the world’s first computationally-designed de novo protein therapeutic.

Our Approach

Neoleukin is a pioneer in de novo protein development, leveraging computational methods to create new therapies.

Learn More


A committed team, dedicated to building an enduring company in service of the science, patients, employees, and the community.

Learn More


A broad set of programs spanning multiple indications, including cancer and autoimmune diseases.

Learn More


Founded on seminal research, as featured in Nature, heralding a new era of custom protein design.

Learn More